Search peptides, terms, sources/
Regulatory source

MHRA reminds healthcare professionals to advise patients of the side effects of GLP-1 agonists and to report misuse

About this source

Kind
Regulatory or official document
Primary or secondary
primary
Retraction status
None known
Date checked
14 August 2026

Limitations

Class-wide GLP-1 notice, not semaglutide-specific.

Cited in

Spotted an error? Report a problem with this page. We correct the record and log every change on What's changed.